Translational Research
Translational research in the biotech industry is an exciting cross functional field between preclinical R&D and clinical research. We are honored to have three director level speakers with extensive experience in translational science to share their journey in the biotech industry and career development in translational research. All of them have 10+ years of experience in Immuno Oncology and are experts and leaders in the translational field. If you are interested in a career in translational research or just curious to know more about the field, don’t miss this exciting session! |
Panelist
Dr. I-Ming Wang
Director of Translational Oncology, Pfizer |
I-Ming Wang received his B.S. in Biology from National Taiwan University, Ph.D. in Molecular Immunology from Baylor College of Medicine, and post-doctoral training at the National Institutes of Health (NIH).
He has 25 years’ experience working in the pharmaceutical industry with more than 50 publications in peer-reviewed scientific journals. Before joining Pfizer in 2017, he spent 14 years at Merck as the Molecular Profiling Site Head at Merck’s West Point site in Pennsylvania focusing on Translational/Precision Medicine in multiple disease/functional areas including oncology, vaccine, infectious diseases, safety assessment, bioprocess, and immunology. He currently serves as a Director of Clinical Research and Translational Oncology Lead at Pfizer for multiple phase 1 oncology clinical trials with assets including epigenomic drugs, targeted immune-therapeutics such as bi-specific antibodies, antibody-drug conjugates, engineered cytokine-antibody fusion proteins, cancer vaccines and oncolytic viruses. |
Moderator
Juo-Chin (Robin) Yao
Scientist, Appia Bio Robin received her bachelor’s degree from National Tsing Hua University and her PhD degree from Washington University in St. Louis. Her graduate research focused on the role of bone marrow microenvironment in normal and malignant hematopoiesis. She is currently a Scientist at Appia Bio working on hematopoietic stem cell derived allogeneic cell therapy for blood cancers and solid tumors. |